1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          Hypertension is a major contributor to cardiac diastolic dysfunction. Different therapeutics strategies have been proposed to control blood pressure (BP), but their independent impact on cardiac function remains undetermined. In patients with resistant hypertension, we compared the changes in cardiac parameters between two strategies based on sequential nephron blockade (NBD) with a combination of diuretics or sequential renin‐angiotensin system blockade (RASB).

          Methods and results

          After a 4‐week period where all patients received Irbesartan 300 mg/day + hydrochlorothiazide 12.5 mg/day + amlodipine 5 mg/day, 140 resistant hypertension patients (54.8 ± 11.1 years, 76% men, mean duration with hypertension: 13.1 ± 10.5 years, no previous history of heart failure or current symptoms of congestive heart failure) were randomized 1:1 to the NBD regimen or to the RASB regimen at week 0 (W0, baseline). Treatment intensity was increased at week 4, 8, or 10 if home BP was ≥135/85 mmHg, by sequentially adding 25 mg spironolactone, 20–40 mg furosemide, and 5 mg amiloride (NBD group) or 5–10 mg ramipril and 5–10 mg bisoprolol (RASB group). No other antihypertensive drug was allowed during the study. BP, BNP levels, and echocardiographic parameters were assessed at weeks 0 and 12.

          The baseline characteristics, laboratory parameters, and plasma hormones (BNP, renin, and aldosterone) and cardiac echocardiographic parameters did not significantly differ between the NBD and the RASB groups. Over 12 weeks, BNP levels significantly decreased in NBD but increased in RASB (mean [CI 95%] change in log‐transformed BNP levels: −43% [−67%; −23%] vs. +55% [46%; 62%] in NBD vs. RASB, respectively, P < 0.0001). Similarly, the proportion of patients presenting ≥2 echocardiographic criteria of diastolic dysfunction decreased between baseline and W12 from 31% to 3% in NBD but increased from 19% to 32% in RASB ( P = 0.0048). As compared with RASB, NBD induced greater decrease in ambulatory systolic BP ( P < 0.0001), pulse pressure ( P < 0.0001), and systemic vascular resistance ( P < 0.005). In multivariable linear regression analyses, NBD treatment was significantly associated with decreased BNP levels (adjusted ß: −46.41 ± 6.99, P < 0.0001) independent of age, gender, renal function, and changes in BPs or heart rate.

          Conclusions

          In patients with resistant hypertension, nephron blockade with a combination of diuretics significantly improves cardiac markers of diastolic dysfunction independently of BP lowering.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.

          This study investigated the effect of catheter-based renal sympathetic denervation (RD) on left ventricular hypertrophy (LVH) and systolic and diastolic function in patients with resistant hypertension. LVH and diastolic dysfunction are associated with elevated sympathetic activity and increased morbidity and mortality. The effect of RD on LVH and LV function is unclear. Forty-six patients underwent bilateral RD, and 18 patients served as controls. Transthoracic echocardiography was performed at baseline, and after 1 month and 6 months. Besides reduction of systolic and diastolic blood pressure (-22.5/-7.2 mm Hg at 1 month and -27.8/-8.8 mm Hg at 6 months, p < 0.001 at each time point), RD significantly reduced mean interventricular septum thickness from 14.1 ± 1.9 mm to 13.4 ± 2.1 mm and 12.5 ± 1.4 mm (p = 0.007), and LV mass index from 53.9 ± 15.6 g/m(2.7) (112.4 ± 33.9 g/m(2)) to 47.0 ± 14.2 g/m(2.7) (103.6 ± 30.5 g/m(2)) and 44.7 ± 14.9 g/m(2.7) (94.9 ± 29.8 g/m(2)) (p < 0.001) at 1 month and 6 months, respectively. The mitral valve lateral E/E' decreased after RD from 9.9 ± 4.0 to 7.9 ± 2.2 at 1 month and 7.4 ± 2.7 at 6 months (p < 0.001), indicating reduction of LV filling pressures. Isovolumic relaxation time shortened (baseline 109.1 ± 21.7 ms vs. 85.6 ± 24.4 ms at 6 months, p = 0.006), whereas ejection fraction significantly increased after RD (baseline: 63.1 ± 8.1% vs. 70.1 ± 11.5% at 6 months, p < 0.001). No significant changes were obtained in control patients. Besides the known effect on blood pressure, our study showed for the first time that RD significantly reduces LV mass and improves diastolic function, which might have important prognostic implications in patients with resistant hypertension at high cardiovascular risk. Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

            Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage. We evaluated the characteristics of 279 consecutive patients with resistant hypertension (uncontrolled despite the use of 3 antihypertensive agents) and 53 control subjects (with normotension or hypertension controlled by using
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry.

              Pulse pressure (PP) provides valuable prognostic information in specific populations, but few studies have assessed its value on cardiovascular outcomes in a broad, worldwide population.
                Bookmark

                Author and article information

                Contributors
                jean-sebastien.hulot@aphp.fr
                Journal
                ESC Heart Fail
                ESC Heart Fail
                10.1002/(ISSN)2055-5822
                EHF2
                ESC Heart Failure
                John Wiley and Sons Inc. (Hoboken )
                2055-5822
                29 June 2020
                October 2020
                : 7
                : 5 ( doiID: 10.1002/ehf2.v7.5 )
                : 2561-2571
                Affiliations
                [ 1 ] Centre d'Investigations Cliniques CIC1418, AP‐HP Hôpital Européen Georges Pompidou Paris France
                [ 2 ] Paris Cardiovascular Research Center PARCC, INSERM Université de Paris Paris France
                [ 3 ] Assistance Publique Hôpitaux de Paris, Hypertension unit Hôpital Européen Georges Pompidou Paris France
                [ 4 ] Assistance Publique Hôpitaux de Paris, Pharmacology department Hôpital Européen Georges Pompidou Paris France
                Author notes
                [*] [* ] Correspondence to: Pr Jean‐Sébastien Hulot, UMR 970, PARCC, 56 Rue Leblanc, Paris, France. Tel: +33 1 56 09 20 17; Fax: +33. Email: jean-sebastien.hulot@ 123456aphp.fr

                Article
                EHF212832 ESCHF-19-00268
                10.1002/ehf2.12832
                7524081
                32597565
                c10b16fa-958d-480e-8528-5f5da019d117
                © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 05 September 2019
                : 19 April 2020
                : 23 May 2020
                Page count
                Figures: 3, Tables: 4, Pages: 11, Words: 4076
                Funding
                Funded by: Ministère de la santé (FR) , open-funder-registry 10.13039/501100004690;
                Award ID: PHRC P040407
                Categories
                Original Research Article
                Original Research Articles
                Custom metadata
                2.0
                October 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.1 mode:remove_FC converted:29.09.2020

                heart failure,resistant hypertension,pharmacology,clinical trials

                Comments

                Comment on this article